Clinical trials: Renal Failure, End Stage
Latent Tuberculosis, Kidney Failure
Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
Objective To determine if treatment completion with a 4-month rifampin (4R) or 3-month rifapentine (P) + isoniazid (H) weekly for 12 weeks (3HP) regimens is better than with a 3-month (3HR) regimen for treatment of latent…
- Trial name
- NCT05021731
- Testing
- Rifampicin plus Isoniazid, Rifapentine plus Isoniazid, Rifampicin alone
- Volunteers
- 225 people
- Sponsor
- Miguel Santín
Cardiovascular Diseases, Carotid Intimal Media Thickness
Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Cardiovascular disease (CVD) is the major risk factor for death in end stage renal diseases (ESRD). Approximately 80% of ESRD patients have some degrees of left ventricular abnormalities at initiation of dialysis.
- Conditions
- Cardiovascular Diseases, Carotid Intimal Media Thickness, Left Ventricular Hypertrophy, Mean Platelet Volume
- Trial name
- NCT03759002
- Testing
- Imaging, Blood sampling
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Chronic Renal Failure, Anemia
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis
This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.
- Trial name
- NCT00111995
- Testing
- Aranesp®
- Volunteers
- 400 people
- Sponsor
- Amgen
Human Immunodeficiency Virus, End Stage Renal Disease
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), published Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for…
- Trial name
- NCT05159466
- Testing
- Kidney transplant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tulane University
End-stage Renal Disease (ESRD), Peritoneal Dialysis (PD)
Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients
The goal of this clinical trial is to assess whether Amino Acid (15) Peritoneal Dialysis Solution can improve the nutritional status of adults with end-stage kidney disease who have received peritoneal dialysis for 6 months or…
- Conditions
- End-stage Renal Disease (ESRD), Peritoneal Dialysis (PD), Nutritional Status, Renal Replacement Therapy
- Trial name
- AA15-PD-Nut-SH (NCT07370441)
- Testing
- amino acid (15) peritoneal dialysis solution
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai 10th People's Hospital
End-Stage Kidney Disease
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys.
- Trial name
- NCT00143741
- Testing
- Atorvastatin (Lipitor)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
End Stage Renal Disease, Chronic Kidney Disease Stage 5
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
- Trial name
- NCT01764854
- Testing
- AZD1722 (in-patient), AZD1722 (out-patient)
- Where
- 3 sites in United States
- Volunteers
- 88 people
- Sponsor
- Ardelyx
Chronic Renal Failure
Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.
The Heparin form a complex with a plasma protein, antithrombin III (ATIII), which is an endogenous anticoagulant. This complex inhibits the formation of thrombin and accelerates its destruction.
- Trial name
- Heparin (NCT01229072)
- Testing
- Heparin sodic, heparin liquemine
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
Restless Legs Syndrome, End Stage Renal Disease
Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD
Restless legs syndrome (RLS) is a neurologic disorder characterized by 1) an urge to move the legs, 2) uncomfortable sensations in the legs, 3) symptoms that are often worse the evening or when at rest , and 4) may be temporarily…
- Trial name
- NCT03708237
- Testing
- Ropinirole, Gabapentin
- Where
- 4 sites in Canada
- Volunteers
- 3 people
- Sponsor
- University of Alberta
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Peritoneal Dialysis, Renal Disease, End-Stage
Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?
Hepatitis B virus causes inflammation of the liver which is detrimental to the end-stage renal disease patients on dialysis. Hepatitis B vaccine is recommended for this high-risk population although the vaccine protection remains…
- Trial name
- NCT00125775
- Testing
- Engerix-B
- Where
- Hong Kong
- Volunteers
- 130 people
- Sponsor
- Chinese University of Hong Kong
End Stage Renal Disease, Depression
Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis
Depression is second in frequency only to hypertension as a comorbid condition for End Stage Renal Disease (ESRD) patients. The presence of depression has been linked to lower quality of life, more medical comorbidities and…
- Trial name
- NCT00618475
- Testing
- Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End-stage Renal Disease
Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation
The purpose of this study is to determine whether psychological intervention is effective in improving quality of life, mood, and relationships among adults with end-stage renal disease who are awaiting kidney transplantation.
- Trial name
- NCT00428012
- Testing
- Quality of Life Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Beth Israel Deaconess Medical Center
Kidney Failure, Chronic
Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
The primary objective of the study was to compare the single dose pharmacokinetics of alisporivir in subjects with end stage renal disease (ESRD) on hemodialysis to those of matched healthy subjects.
- Trial name
- NCT01975337
- Testing
- Alisporivir
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Debiopharm International SA
End Stage Renal Disease
Percutaneous Translumbar Vs Transhepatic Permcath
The aim of the study is to emphasize the technique , success rate , efficacy of translumbar and transhepatic approaches and shed light on the complications of both methods and through comparison we can give recommendations to…
- Trial name
- NCT05666375
- Testing
- Percutaneous translumbar and transhepatic permcath
- Volunteers
- 52 people
- Sponsor
- Assiut University
Renal Failure, End Stage Renal Disease
Comparison of Efficacy and Tolerability of APD Treatment With Different PD Cyclers
The study has been designed in order to investigate the performance and safety of the new Silencia PD cycler including the Silencia tubing system in comparison to the PD-Night and Homechoice PD cycler which are both…
- Trial name
- NCT04749680
- Testing
- PD cycler Silencia
- Where
- 4 sites in Chile
- Volunteers
- 16 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
End Stage Renal Disease, Hyperparathyroidism, Secondary
Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease
The MBD-5D is a prospective observational study with a case-cohort and a cohort design. Eligible patients are receiving hemodialysis and have secondary hyperparathyroidism.
- Trial name
- MBD-5D (NCT00995163)
- Where
- Japan
- Volunteers
- 8,020 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Renal Impairment
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3866 is removed from the…
- Trial name
- NCT03259087
- Testing
- MK-3866
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcus Aureus Infection
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
This is a study to evaluate the safety and immunogenicity of V710 with and without Merck Aluminum Adjuvant (MAA) in adult participants with end-stage kidney disease who are on hemodialysis.
- Trial name
- NCT00572910
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia, Kidney Failure, Chronic
A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.
- Trial name
- NCT01999582
- Testing
- Sotatercept
- Where
- 23 sites in Belgium, Germany and 3 more
- Volunteers
- 50 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.